QCM Cayman’s Atossa Therapeutics ATOS Stock Holding History

QCM Cayman’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,487	Closed	-$36K	–	90
2021 Q4	$36K	Buy	+1,487	New	+$54.4K	0.22%	64

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

QCM Cayman's ATOS Position: Q1 2022 in Review

QCM Cayman sold out of Atossa Therapeutics (ATOS) in Q1 2022, closing a stake of 1,487 shares — an estimated $36K sold.

QCM Cayman first reported a position in ATOS in Q4 2021 and held it in 1 quarter. The position peaked at $36K in Q4 2021. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2022.

QCM Cayman reported no remaining Atossa Therapeutics position as of Q1 2022 after selling out during the quarter.
QCM Cayman sold 1,487 Atossa Therapeutics shares in Q1 2022, an estimated $36K.
QCM Cayman first reported a position in Atossa Therapeutics in Q4 2021 and held it in 1 quarter.
QCM Cayman's Atossa Therapeutics position peaked at $36K in Q4 2021.
83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2022.

Based on QCM Cayman's 13F filing for Q1 2022, filed 6 May 2022.